Specify a stock or a cryptocurrency in the search bar to get a summary
Kopran Limited
KOPRANKopran Limited, an integrated pharmaceutical company, engages in the manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-acne, anti-infective, anti-thrombotic, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company provides drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India. Address: Parijat House, Mumbai, India, 400018
Analytics
WallStreet Target Price
6 251.2 INRP/E ratio
25.0041Dividend Yield
1.34 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures KOPRAN
Dividend Analytics KOPRAN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
29 %Dividend History KOPRAN
Stock Valuation KOPRAN
Financials KOPRAN
Results | 2019 | Dynamics |